Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.58 USD | +1.57% |
|
-1.90% | -87.41% |
Jul. 05 | Leerink Upgrades AN2 Therapeutics to Outperform Rating With $5 Price Target | MT |
Jul. 03 | Leerink Partners Upgrades AN2 Therapeutics to Outperform From Market Perform, Price Target is $5 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.41% | 75.77M | |
+22.10% | 47.07B | |
+46.45% | 42.06B | |
-3.12% | 39.98B | |
+36.10% | 33.02B | |
-6.30% | 27.9B | |
+18.71% | 27.63B | |
+46.15% | 14.37B | |
+44.52% | 13.45B | |
+0.19% | 12.03B |
- Stock Market
- Equities
- ANTX Stock
- News AN2 Therapeutics, Inc.
- Leerink Partners Upgrades AN2 Therapeutics to Outperform From Market Perform, Price Target is $5